Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Zimmer Biomet Holdings has filed a Form S-8 to register securities under its 2009 Stock Incentive Plan. The company, a large accelerated filer headquartered in Warsaw, Indiana, is registering additional shares for employee benefits.
Key aspects of the filing include:
- Registration covers the amended and restated 2009 Stock Incentive Plan (referenced in 8-K filed June 3, 2025)
- Filing incorporates by reference several documents including the Annual Report for FY2024, Quarterly Report for Q1 2025, and proxy materials
- Includes comprehensive indemnification provisions for directors and officers under Delaware law
- Company maintains directors' and officers' liability insurance coverage
The filing includes standard undertakings regarding post-effective amendments and removal of unsold securities. Legal opinion and consent from PricewaterhouseCoopers LLP are filed as exhibits. This registration statement enables Zimmer Biomet to offer equity-based compensation to employees under its incentive plan.